Physician Assistant · Reno, NV
NPI
1174652143
Since 2007
Specialty
Physician Assistant
Code 363A00000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
10085 Double R Blvd, Ste 310
Reno, NV, 89521
Phone (775) 982-7260
Groups this clinician bills Medicare through
Medicare paid, 2024
$67K
1,452 services
Medicare patients, 2024
295
Average age 72
Drug cost, 2024
$8.1M
5,605 prescriptions
Company payments, 2025
$4,464
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Benjamin D Prohaska was code 99214 (office e&m - established), 600 times for 258 patients. In total Benjamin D Prohaska billed 1,452 services in 8 codes, and Medicare paid $67K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 600 | 258 | $74.89 | $45K |
| 83036 Blood Count | Office | 390 | 225 | $9.47 | $3,695 |
| 95251 Test - Miscellaneous | Office | 303 | 143 | $20.39 | $6,178 |
| 99204 Office E&M - New | Office | 95 | 95 | $94.70 | $8,996 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 57 | 54 | $10.61 | $605 |
By year: 2022 $59K for 1,006 services; 2023 $73K for 1,419 services; 2024 $67K for 1,452 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 390 | 225 | $9.47 | $3,695 |
Medicare prescription drug claims, 2024
In 2024, the drug Benjamin D Prohaska prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 960 prescriptions and refills. In total Benjamin D Prohaska wrote 5,605 Medicare prescriptions that cost $8.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 960 | 1,330 | 169 | $1.4M |
| Ozempic Semaglutide | 742 | 1,300 | 169 | $1.2M |
| Pioglitazone Hcl Generic | 491 | 1,330 | 165 | $9,408 |
| Synjardy Xr Empagliflozin/Metformin Hcl | 481 | 1,120 | 146 | $632K |
| Jardiance Empagliflozin | 414 | 963 | 141 | $551K |
| Tresiba Flextouch U-200 Insulin Degludec | 270 | 525 | 77 | $263K |
| Levothyroxine Sodium Generic | 197 | 561 | 62 | $2,478 |
| Trulicity Dulaglutide | 145 | 269 | 40 | $254K |
| Novolog Flexpen Insulin Aspart | 131 | 260 | 56 | $31K |
| Metformin Hcl Er Metformin Hcl | 122 | 358 | 50 | $1,175 |
| Tresiba Flextouch U-100 Insulin Degludec | 114 | 267 | 44 | $79K |
| Atorvastatin Calcium Generic | 100 | 296 | 32 | $874 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 92 | 187 | 31 | $13K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 83 | 223 | 41 | $13K |
| Xigduo Xr Dapaglifloz Propaned/Metformin | 63 | 173 | 19 | $96K |
Brand drugs: 4,145 claims; generic drugs: 1,289 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Benjamin D Prohaska $4,464 ($4,464 in general payments such as food, travel and fees) from 18 companies. The largest payer was Novo Nordisk Inc with $1,780.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 11 | $1,780 |
| Medtronic, Inc. MDT | 32 | $451 |
| Mannkind Corporation MNKD | 21 | $392 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $264 |
| Xeris Pharmaceuticals, Inc. | 18 | $250 |
| Corcept Therapeutics CORT | 15 | $240 |
| Amgen Inc. AMGN | 11 | $233 |
| Recordati_rare_diseases_inc. | 12 | $204 |
| Lilly USA, LLC LLY | 10 | $188 |
| Sanofi-Aventis U.S. LLC SNY | 5 | $106 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.